FDA ‘Encouraging Evergreening’ With Strength Definition – Boehringer Ingelheim

Minor Concentration Changes Being Used As ‘Anticompetitive Tactic’

 
• By Dean Rudge
  
US FDA entrance sign
The FDA's definition of strength for injectable biologics is "arbitrary and capricious," Boehringer insists. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products